Format

Send to

Choose Destination
See comment in PubMed Commons below
ARYA Atheroscler. 2012 Winter;7(4):133-7.

The effects of pentoxifylline administration on NFΚB P50 transcription factor expression.

Author information

1
PhD, Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

BACKGROUND:

Pentoxifylline has anti-inflammatory properties and could suppress some inflammatory processes including tumor necrosis factor-alpha (TNF-α) production. We assessed the effects of a two-month administration of pentoxifylline on nuclear factor-kappa B (NFκB) pathways in patients with coronary artery disease (CAD) in which inflammatory pathways, especially NFκB transcription factors, have a critical role.

METHODS:

A double-blind randomized placebo-controlled study design was used. Forty CAD patients were randomized to either 2 months of pentoxifylline treatment (1200 mg/day) (n = 20) or placebo treatment (n = 20). Blood samples were obtained just before and after two months of treatment. P50 protein concentration in peripheral blood mononuclear cells (PBMCs) was measured by Enzyme Linked ImmunoSorbent Assay (ELISA) method.

RESULTS:

P50 concentration did not significantly change during two months of pentoxifylline administration.

CONCLUSION:

Longer pentoxifylline administration is needed to see its favorable effects on NFκB family elements.

KEYWORDS:

Coronary Artery Diseases; Inflammation; NFκB; Pentoxifylline

PMID:
23205044
PMCID:
PMC3413080
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center